American society of hematology 49th annual meeting.
نویسنده
چکیده
In a clinical trial among 187 patients with paroxysmal nocturnal hemolysis (PNH), treatment with eculizumab (Soliris, Alexion), a terminal complement inhibitor, significantly reduced hemolysis and thrombosis and improved anemia and fatigue in several participating subgroups. Dr. Bessler noted that the disease burden had not previously been determined in these patients, who had lower lactate dehydrogenase (LDH) levels, higher hemoglobin values, and minimal transfusion support. Patients who had been enrolled in eculizumab trials (phase 2 pilot, phase 3 TRIUMPH, and SHEPHERD studies) and who continued to receive eculizumab in a long-term extension trial for a median of 22 months’ duration were stratified as follows:
منابع مشابه
Advances in the treatment of myelodysplastic syndromes.
A Review of Selected Presentations From the 49th American Society of Hematology Annual Meeting and Exposition, December 8-11, 2007, Atlanta, Georgia.
متن کاملRecent advances in the treatment of lymphoma.
A Review of Selected Presentations From the 49th American Society of Hematology Annual Meeting and Exposition, December 8-11, 2007, Atlanta, Georgia.
متن کاملAmerican Society of Hematology 2015 Annual Meeting.
The annual meeting of the American Society of Hematology drew 25,000 attendees for the presentation of 5,633 abstracts. We review key sessions focusing on newer agents and their efficacy in high-risk leukemia and multiple myeloma populations.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- P & T : a peer-reviewed journal for formulary management
دوره 33 2 شماره
صفحات -
تاریخ انتشار 2008